A Oliver Sartor
Affiliation: Tulane University
- Manogue C, Ledet E, Guddati A, Lewis B, Sartor O. Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer. Oncologist. 2018;23:383-385 pubmed publisher..We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies. ..
- Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O Sullivan J, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738-46 pubmed publisher..We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases...
- Crawford E, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017;35S:S1-S13 pubmed publisher..The treatment of advanced prostate cancer and the research related to biomarkers are discussed. ..
- Sartor O, Vogelzang N, Sweeney C, Fernandez D, Almeida F, Iagaru A, et al. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018;23:193-202 pubmed publisher..Patients with more advanced disease were less likely to benefit from radium-223. Clinicians should consider baseline clinical characteristics and therapy sequence to provide the greatest clinical value to patients. ..